RecruitingNot applicableNCT02652169

PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4

Studying Rapidly involuting congenital hemangioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medical University of Vienna
Principal Investigator
Florian Thalhammer, Prof. Dr.
Medical University of Vienna
Intervention
PRF mixed with amikacin and teicoplanin(drug)
Enrollment
120 target
Eligibility
18 years · All sexes
Timeline
20142027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02652169 on ClinicalTrials.gov

Other trials for Rapidly involuting congenital hemangioma

Additional recruiting or active studies for the same condition.

See all trials for Rapidly involuting congenital hemangioma

← Back to all trials